Innovent Biologics shares rise 10% after pact with Pfizer of up to $10.5 billion
Innovent Biologics' shares increased by 10% following a significant partnership with Pfizer to develop oncology medicines. The agreement includes licensing, co-development, and co-commercialization of a portfolio of cancer treatments, with Innovent retaining rights in Greater China. The deal is valued at up to $10.5 billion, including an upfront payment and potential milestone payments.
- ▪Innovent Biologics shares rose 10% after a deal with Pfizer.
- ▪The partnership involves the development of 12 early-stage cancer medicines.
- ▪Innovent will receive an upfront payment of $650 million and could earn up to $9.85 billion in milestone payments.
3 outlets in our directory ran this story, first to last over 3 hours. All of the coverage we found sits in one bucket: centre. That one-sidedness is itself worth noticing.
- ▪ Innovent Biologics Surges After Signing Up to $10.5 Billion Deal With Pfizer - Morningstar — Google News
- ▪ China’s Innovent Biologics signs US$10.5 billion Pfizer deal for 12 cancer drug trials — South China Morning Post
CNBC — Top files mainly under finance. We currently carry 510 of its stories.
Story provenance
Source · retrieval · rights · ranking — open for full record
inspect →
Story provenance
Attribution is not the same as permission. This drawer separates discovery metadata, excerpts, WeSearch-generated summaries, reuse status, and whether the publisher receives the visit. Nothing here claims a legal grant the publisher has not made.
Record
| Original publisher | CNBC — Top |
| Canonical URL | https://www.cnbc.com/2026/05/29/innovent-shares-rise-10percent-after-pact-with-pfizer-of-up-to-10point5-billion.html |
| Publication time | Fri, 29 May 2026 03:10:55 GMT |
| Retrieval time | 2026-05-29T03:14:40.949Z |
| Last seen | 2026-05-29T03:14:40.949Z |
| Headline source | Publisher (no WeSearch rewrite) |
| Excerpt source | publisher body |
| Excerpt method | First ~120 words (~800 chars) of extracted publisher body, fair-use limited. |
| Summary | WeSearch · cerebras-chat (WeSearch summarizer) |
| Summary source text | contentText |
| Citation coverage | Summary is a WeSearch-generated derivative; primary citation is the original publisher URL. |
| Cluster | AlcHXioZ_fK5 · 3 stories |
| Cluster logic | Grouped by semantic title/content similarity across sources within a rolling window. Same-publisher template collisions are excluded from coverage comparison. |
| Ranking reason | Story pages are not engagement-ranked. Hub feeds use recency, with optional source-diversified chronological ordering (cap consecutive stories per source). No personalized ranking. |
| Publisher visit | Yes — open original |
| Substitutes article? | No — link-out required for full text |
Rights status (four layers)
WeSearch handling by dimension
| Indexing | May the item be indexed (stored, ranked, made findable)? | Allowed |
| Snippet | May a short excerpt of the publisher's text be shown? | Allowed |
| AI summary | May WeSearch generate its own short summary of the article? | Limited |
| Retrieval / RAG | May the content be exposed for third-party retrieval-augmented generation? | Not asserted |
| Model training | May the content be used to train AI models? | Not asserted |
| Commercial reuse | May the content be reused commercially? | Not permitted |
Basis: Derived from the published RSS/Atom feed. Contact: [email protected]. Reviewed: 2026-07-24.
Opening excerpt (first ~120 words) tap to expand
Shares of Innovent Biologics rose 10% after the company entered into a deal with pharmaceutical giant Pfizer to develop oncology medicines. The partnership, which includes licensing, co-development, and co-commercialization opportunities across a diverse portfolio of antibody-drug conjugates, will involve the research and development of 12 breakthrough early-stage and de novo cancer medicines, the company said in a filing. Innovent will develop four global programs with Pfizer, sharing costs. In addition, the Hong Kong-listed biotech company will co-commercialize with Pfizer in the U.S. and Europe and share profits, though Innovent will retain rights to these programs in the Greater China market.
…
Excerpt limited to ~120 words for fair-use compliance. The full article is at CNBC — Top.
Discussion
0 commentsMore from CNBC — Top
